Metabolic and Bariatric Surgery · 1 March 2025

Metabolic and bariatric surgery reduces cardiovascular risks in obesity.

A comparative analysis of metabolic and bariatric surgery (MBS) versus glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy indicated that MBS significantly lowers the hazard of cardiovascular disease in patients with obesity. Specifically, MBS demonstrated a reduced risk for the primary composite outcome of cardiovascular disease (HR 0.54) and secondary outcomes including heart failure (HR 0.45), coronary artery disease (HR 0.54), and cerebrovascular disease (HR 0.64) over up to 10 years of follow-up.

Journal Article by Maan S, Sohail AH (…) Singh S et 8 al. in Am J Surg

read the whole article in Am J Surg

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Metabolic and Bariatric Surgery.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

The latest stitches

Surg Endosc29 Sep 2026

Endoscopic Sleeve Gastroplasty Offers Safer Alternative to LSG

Endoscopic sleeve gastroplasty (ESG) provides moderate weight loss with a lower risk of complications compared to laparoscopic sleeve gastrectomy (LSG), making it a viable option for patients, particularly those with existing gastro-esophageal reflux disease (GERD).

Ann Surg13 Jul 2026

Predictive Models Enhance Diabetes Remission After Surgery

A new calculator predicts type 2 diabetes remission outcomes for patients post-metabolic surgery, improving patient selection.

Ann Surg16 Jun 2026

EndoBarrier Shows Promise for Type 2 Diabetes in Obesity

Endoscopic duodenal-jejunal bypass liner may significantly improve glycemic control and weight loss in patients with poorly controlled type 2 diabetes and obesity.

All papers in Metabolic and Bariatric Surgery →